SYK Stock Analysis — Stryker Corporation
Sector: Healthcare
AI Verdict
Stryker trades at 19.6x next year’s earnings with 93% EPS growth expected, making it cheap for the growth you’re getting if its hospital lock-in and robotics moat hold up.
Competitive Moat
Stryker dominates in orthopedic implants and surgical equipment, benefiting from deep hospital relationships and high switching costs for its specialized devices. Its recurring revenue from consumables and proprietary surgical robotics platform further locks in customers and deters competitors.
Summary
Stryker’s sharp drop in forward P/E to 19.6x, paired with a massive 93% expected EPS growth, puts it on value watch after a tough year.
Where It Stands
Shares are down -17.14% over the past year, the RSI at 63.1 signals a neutral-to-elevated zone, and the forward P/E of 19.6x is below the healthcare sector median of 22x despite huge growth forecasts.
Key Metrics
- RSI: 63.1 — Near Overbought
- Trailing P/E: 37.9x
- Forward P/E: 19.6x
- PEG Ratio: 0.41
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- Market Cap: $126.5B
- Dividend Yield: 0.01%
- 1-Year Return: -17.14%
- 52-Week High: $404.87
- 52-Week Low: $281.00
Analyst Consensus
27 Buy · 8 Hold · 0 Sell (35 analysts)
Bull Case
With analysts projecting 93.0% EPS growth and a forward P/E of just 19.6x, you’re getting explosive earnings momentum at a discount to the sector median.
Bear Case
If the forward P/E reverts to the trailing 37.9x, that would imply a 93% price jump — so any growth disappointment could see the stock punished as expectations are sky-high.
Catalyst to Watch
Watch for upcoming earnings reports to confirm whether the forecasted 93% EPS growth materializes, as a miss could trigger a sharp rerating.